Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II first-line irinotecan liposome combination study in metastatic colorectal cancer
ChiCTR2600132938Phase 2Not yet recruiting
- Sponsor
- Shanxi Cancer Hospital
- Start
- Dec 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan liposome, fluorouracil, folinic acid, PBI-1308, bevacizumab and 1 more in colorectal cancer (CRC), sponsored by Shanxi Cancer Hospital. Primary endpoint: objective response rate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
irinotecan liposomefluorouracilfolinic acidPBI-1308bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2600132938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132938.